1. Home
  2. ACAD vs PPLI Comparison

ACAD vs PPLI Comparison

Compare ACAD & PPLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$24.84

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Logo People Incorporated Common Stock

PPLI

People Incorporated Common Stock

N/A

Current Price

$41.69

Market Cap

3.5B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ACAD
PPLI
Founded
1993
N/A
Country
United States
United States
Employees
N/A
5156
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Programming Data Processing
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
4.3B
3.5B
IPO Year
2000
N/A

Fundamental Metrics

Financial Performance
Metric
ACAD
PPLI
Price
$24.84
$41.69
Analyst Decision
Buy
Analyst Count
22
0
Target Price
$30.55
N/A
AVG Volume (30 Days)
1.7M
821.9K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
69.12
N/A
EPS
0.02
N/A
Revenue
$726,437,000.00
N/A
Revenue This Year
$18.80
N/A
Revenue Next Year
$11.70
N/A
P/E Ratio
$1,241.50
N/A
Revenue Growth
40.45
N/A
52 Week Low
$19.69
$41.05
52 Week High
$28.35
$48.32

Technical Indicators

Market Signals
Indicator
ACAD
PPLI
Relative Strength Index (RSI) 51.72 43.43
Support Level $20.56 $41.78
Resistance Level $25.36 $48.21
Average True Range (ATR) 0.76 1.20
MACD -0.26 -0.63
Stochastic Oscillator 23.84 0.85

Price Performance

Historical Comparison
ACAD
PPLI

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About PPLI People Incorporated Common Stock

People Inc is a media and publishing business that operates a portfolio of brands, including PEOPLE, Food & Wine, Travel + Leisure, InStyle, Better Homes & Gardens, and Southern Living. The company also holds a minority equity stake in MGM Resorts International.

Share on Social Networks: